CANGENE WINS $17M BRITISH CONTRACT FOR VACCINIA SMALLPOX TREATMENT

The British government has awarded a $17-million contract to Cangene Corp. of Winnipeg for the supply of Vaccinia immune globulin, of VIG, used in preventing a severe reaction to the smallpox vaccine. Cangene (TSX:CNJ) said Monday it expects to complete delivery of VIG to the U.K. Department of Health by the end of its 2006 fiscal year. "As well as some smaller orders, this is the third significant government purchase of this product, which was recently approved by the U.S. Food and Drug Administration," John Langstaff, CEO of Cangene, said in a release.

Canada.com (http://www.canada.com/health/story.html?id=eefe4fb7-737a-4653-a289-58f8bd79a7ec)